Pedersen Natalia, Andersen Nynne Nyboe, Végh Zsuzsanna, Jensen Lisbeth, Ankersen Dorit Vedel, Felding Maria, Simonsen Mette Hestetun, Burisch Johan, Munkholm Pia
Natalia Pedersen, Johan Burisch, Pia Munkholm, Digestive Disease Centre, Medical Section, Herlev University Hospital, 2730 Copenhagen, Denmark.
World J Gastroenterol. 2014 Nov 21;20(43):16215-26. doi: 10.3748/wjg.v20.i43.16215.
To investigate the effects of a low fermentable, oligosaccharides, disaccharides, monosaccharides and polyols diet (LFD) and the probiotic Lactobacillus rhamnosus GG (LGG) in irritable bowel syndrome (IBS).
Randomised, unblinded controlled trial on the effect of 6-wk treatment with LFD, LGG or a normal Danish/Western diet (ND) in patients with IBS fulfilling Rome III diagnostic criteria, recruited between November 2009 and April 2013. Patients were required to complete on a weekly basis the IBS severity score system (IBS-SSS) and IBS quality of life (IBS-QOL) questionnaires in a specially developed IBS web self-monitoring application. We investigated whether LFD or LGG could reduce IBS-SSS and improve QOL in IBS patients.
One hundred twenty-three patients (median age 37 years, range: 18-74 years), 90 (73%) females were randomised: 42 to LFD, 41 to LGG and 40 to ND. A significant reduction in mean ± SD of IBS-SSS from baseline to week 6 between LFD vs LGG vs ND was revealed: 133 ± 122 vs 68 ± 107, 133 ± 122 vs 34 ± 95, P < 0.01. Adjusted changes of IBS-SSS for baseline covariates showed statistically significant reduction of IBS-SSS in LFD group compared to ND (IBS-SSS score 75; 95%CI: 24-126, P < 0.01), but not in LGG compared to ND (IBS-SSS score 32; 95%CI: 18-80, P = 0.20). IBS-QOL was not altered significantly in any of the three groups: mean ± SD in LFD 8 ± 18 vs LGG 7 ± 17, LFD 8 ± 18 vs ND 0.1 ± 15, P = 0.13.
Both LFD and LGG are efficatious in patients with IBS.
研究低可发酵寡糖、双糖、单糖和多元醇饮食（LFD）及益生菌鼠李糖乳杆菌GG（LGG）对肠易激综合征（IBS）的影响。
对2009年11月至2013年4月招募的符合罗马III诊断标准的IBS患者进行一项关于LFD、LGG或正常丹麦/西方饮食（ND）6周治疗效果的随机、非盲对照试验。患者需在一个专门开发的IBS网络自我监测应用程序中每周完成肠易激综合征严重程度评分系统（IBS-SSS）和肠易激综合征生活质量（IBS-QOL）问卷。我们研究了LFD或LGG是否能降低IBS患者的IBS-SSS并改善生活质量。
123名患者（中位年龄37岁，范围：18 - 74岁），90名（73%）女性被随机分组：42名接受LFD，41名接受LGG，40名接受ND。结果显示，从基线到第6周，LFD组、LGG组和ND组的IBS-SSS均值±标准差有显著降低：133±122对比68±107，133±122对比34±95，P<0.01。对基线协变量调整后的IBS-SSS变化显示，与ND组相比，LFD组的IBS-SSS有统计学意义的降低（IBS-SSS评分75；95%CI：24 - 126，P<0.01），但LGG组与ND组相比无显著降低（IBS-SSS评分32；95%CI：18 - 80，P = 0.20）。三组中任何一组的IBS-QOL均无显著改变：LFD组均值±标准差为8±18，LGG组为7±17，LFD组8±18对比ND组0.1±15，P = 0.13。
LFD和LGG对IBS患者均有效。
